1239 related articles for article (PubMed ID: 25593290)
1. Endothelial-to-mesenchymal transition in pulmonary hypertension.
Ranchoux B; Antigny F; Rucker-Martin C; Hautefort A; Péchoux C; Bogaard HJ; Dorfmüller P; Remy S; Lecerf F; Planté S; Chat S; Fadel E; Houssaini A; Anegon I; Adnot S; Simonneau G; Humbert M; Cohen-Kaminsky S; Perros F
Circulation; 2015 Mar; 131(11):1006-18. PubMed ID: 25593290
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic protein-7 inhibits endothelial-mesenchymal transition in pulmonary artery endothelial cell under hypoxia.
Zhang H; Liu Y; Yan L; Du W; Zhang X; Zhang M; Chen H; Zhang Y; Zhou J; Sun H; Zhu D
J Cell Physiol; 2018 May; 233(5):4077-4090. PubMed ID: 28926108
[TBL] [Abstract][Full Text] [Related]
3. In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.
Hopper RK; Moonen JR; Diebold I; Cao A; Rhodes CJ; Tojais NF; Hennigs JK; Gu M; Wang L; Rabinovitch M
Circulation; 2016 May; 133(18):1783-94. PubMed ID: 27045138
[TBL] [Abstract][Full Text] [Related]
4. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
5. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition.
Shi R; Zhu D; Wei Z; Fu N; Wang C; Liu L; Zhang H; Liang Y; Xing J; Wang X; Wang Y
Life Sci; 2018 Aug; 207():442-450. PubMed ID: 29969608
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
7. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
Zakrzewicz A; Hecker M; Marsh LM; Kwapiszewska G; Nejman B; Long L; Seeger W; Schermuly RT; Morrell NW; Morty RE; Eickelberg O
Circulation; 2007 Jun; 115(23):2957-68. PubMed ID: 17515463
[TBL] [Abstract][Full Text] [Related]
8. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension.
Reynolds AM; Holmes MD; Danilov SM; Reynolds PN
Eur Respir J; 2012 Feb; 39(2):329-43. PubMed ID: 21737550
[TBL] [Abstract][Full Text] [Related]
9. The role of PDGF-B/TGF-β1/neprilysin network in regulating endothelial-to-mesenchymal transition in pulmonary artery remodeling.
Song S; Zhang M; Yi Z; Zhang H; Shen T; Yu X; Zhang C; Zheng X; Yu L; Ma C; Liu Y; Zhu D
Cell Signal; 2016 Oct; 28(10):1489-501. PubMed ID: 27373199
[TBL] [Abstract][Full Text] [Related]
10. NF-κB mediated miR-130a modulation in lung microvascular cell remodeling: Implication in pulmonary hypertension.
Li L; Kim IK; Chiasson V; Chatterjee P; Gupta S
Exp Cell Res; 2017 Oct; 359(1):235-242. PubMed ID: 28755990
[TBL] [Abstract][Full Text] [Related]
11. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.
Feng F; Harper RL; Reynolds PN
Respirology; 2016 Apr; 21(3):526-32. PubMed ID: 26689975
[TBL] [Abstract][Full Text] [Related]
12. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
13. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
McMurtry MS; Moudgil R; Hashimoto K; Bonnet S; Michelakis ED; Archer SL
Am J Physiol Lung Cell Mol Physiol; 2007 Apr; 292(4):L872-8. PubMed ID: 17142350
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia induces endothelial‑mesenchymal transition in pulmonary vascular remodeling.
Zhang B; Niu W; Dong HY; Liu ML; Luo Y; Li ZC
Int J Mol Med; 2018 Jul; 42(1):270-278. PubMed ID: 29568878
[TBL] [Abstract][Full Text] [Related]
17. Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Good RB; Gilbane AJ; Trinder SL; Denton CP; Coghlan G; Abraham DJ; Holmes AM
Am J Pathol; 2015 Jul; 185(7):1850-8. PubMed ID: 25956031
[TBL] [Abstract][Full Text] [Related]
18. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
19. Abnormal expression of vesicular transport proteins in pulmonary arterial hypertension in monocrotaline-treated rats.
Zhang H; Luo Q; Liu Z; Wang Y; Zhao Z
Acta Biochim Biophys Sin (Shanghai); 2015 Mar; 47(3):156-63. PubMed ID: 25630652
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
